Sepsis Diagnostics Market: Opportunities and Challenges

 Breaking News
  • No posts were found

Sepsis Diagnostics Market: Opportunities and Challenges

October 16
17:30 2019
Sepsis Diagnostics Market: Opportunities and Challenges

Major key players are bioMérieux (France), Danaher (US), Becton, Dickinson and Company (US), Roche (Switzerland), and Abbott (US). Other players in this market include T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), CytoSorbents (US), and EKF (US)
Factors such as the rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market.

The global sepsis diagnostics market is estimated to reach USD 613.9 million by 2023 from USD 396.6 billion in 2018, at a CAGR of 9.1% from 2018 to 2023.

The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis across the globe. Factors such as the rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are also supporting the growth of this market. However, lack of established reimbursement policies for sepsis and the high cost of automated diagnostic devices are the major factors restraining the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

OPPORTUNITIES

Development of rapid diagnostic/POC techniques for early sepsis diagnosis

Sepsis is a very difficult condition to diagnose as the clinical presentation of sepsis is highly variable depending on etiology. Once the infection sets in, the condition of a patient deteriorates rapidly owing to which early diagnosis is a major area of focus in this market. Mortality rates from sepsis range between 40% to 70% for septic shock and 25% to 30% for severe sepsis (Source: Am Fam Physician. 2013 Jul 1; 88(1):44-53.). Early goal-directed therapy completed within the first six hours of sepsis diagnosis significantly reduces in-hospital mortality. Moreover, early antibiotic therapy helps in improving the clinical outcomes, which leads to improvement in sepsis outcomes, as the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients having hypertension. As a result, slower turnaround times of conventional/manual blood culture methods have created a demand for rapid diagnostic techniques providing faster results. The turnaround time of a conventional/manual blood culture method is more than 24 hours. On the other hand, fully automated blood culture systems offer faster turnaround times (4-6 hours) and also reduce labor costs. In addition, these automated systems can be used for large-scale sample handling and easier processing of challenging specimens.

CHALLENGES

Lack of standard protocols and awareness for sepsis diagnosis and treatment

Lack of consensus on the clinical definition of sepsis and low awareness about sepsis among doctors and nurses is a major challenge in this market. Most physicians do not have an adequate understanding of sepsis as its symptoms are similar to other disease conditions; this often leads to incorrect or delayed examination and diagnosis of sepsis. According to a survey conducted among EMS professionals, awareness among these professionals is less than 10% in pre-hospital providers, who require sufficient knowledge to handle sepsis-focused scenarios. This is due to lack of pre-hospital sepsis dispatch and clinical care protocols across various regions (Source: Prehosp Disaster Med. 2013;28:104–6. doi: 10.1017/S1049023X12001744). Moreover, the protocols set for sepsis diagnosis are often impractical to implement; in some cases, the protocols are too detailed to understand the eventualities, whereas, in other cases, they suggest resources, which are unavailable locally. In 2015, according to a survey conducted by the UK Sepsis Trust, only 16% of the community was aware that sepsis was a time-critical medical condition. These findings mirror similar surveys conducted in Germany and the US. Similarly, according to a survey conducted for the Sepsis Alliance only 44% of the Americans had heard of sepsis. 

Sepsis diagnosis is a difficult process due to a lack of appropriate standard protocols for the identification of this clinical condition. Moreover, hospital staff does not give much priority to patients with sepsis due to a lack of knowledge about sepsis being a medical emergency. Furthermore, in the US, the sepsis guidelines are considered as performance measures to evaluate the quality of the hospital accreditation or physician care, which is another reason for no compliance with these guidelines. Additionally, with the lack of standard protocols, there is a failure to communicate the risk and symptoms of sepsis between in-house hospital departments during clinical data exchange.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155

Browse Related Reports:

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) – Global Forecasts to 2021

Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laboratory), Product & Service (Reagent, Software) – Global Forecast to 2023

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Media Contact
Company Name: MarketsandMarkets
Contact Person: Mr. Shelly Singh
Email: Send Email
Phone: 1-888-600-6441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/sepsis-diagnostic-market-92673155.html

Related Articles

Categories